EP1968559A4 - Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes - Google Patents

Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes

Info

Publication number
EP1968559A4
EP1968559A4 EP06844984.2A EP06844984A EP1968559A4 EP 1968559 A4 EP1968559 A4 EP 1968559A4 EP 06844984 A EP06844984 A EP 06844984A EP 1968559 A4 EP1968559 A4 EP 1968559A4
Authority
EP
European Patent Office
Prior art keywords
diabetes
treatment
metabolic syndrome
botanical products
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06844984.2A
Other languages
German (de)
French (fr)
Other versions
EP1968559A2 (en
Inventor
Matthew L Tripp
John G Babish
Jeff Bland
Amy Jennae Hall
Veera Konda
Linda Pacioretty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MetaProteomics LLC
Original Assignee
MetaProteomics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MetaProteomics LLC filed Critical MetaProteomics LLC
Priority to EP14000382.3A priority Critical patent/EP2737897A3/en
Publication of EP1968559A2 publication Critical patent/EP1968559A2/en
Publication of EP1968559A4 publication Critical patent/EP1968559A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/235—Foeniculum (fennel)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
EP06844984.2A 2005-12-09 2006-12-07 Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes Withdrawn EP1968559A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP14000382.3A EP2737897A3 (en) 2005-12-09 2006-12-07 Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74890705P 2005-12-09 2005-12-09
PCT/US2006/046770 WO2007070355A2 (en) 2005-12-09 2006-12-07 Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP14000382.3A Division EP2737897A3 (en) 2005-12-09 2006-12-07 Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes

Publications (2)

Publication Number Publication Date
EP1968559A2 EP1968559A2 (en) 2008-09-17
EP1968559A4 true EP1968559A4 (en) 2013-08-07

Family

ID=38163414

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06844984.2A Withdrawn EP1968559A4 (en) 2005-12-09 2006-12-07 Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
EP14000382.3A Withdrawn EP2737897A3 (en) 2005-12-09 2006-12-07 Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14000382.3A Withdrawn EP2737897A3 (en) 2005-12-09 2006-12-07 Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes

Country Status (5)

Country Link
EP (2) EP1968559A4 (en)
JP (1) JP2009518429A (en)
AU (1) AU2006326658A1 (en)
CA (1) CA2632607A1 (en)
WO (1) WO2007070355A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008115163A (en) * 2006-10-10 2008-05-22 Kikkoman Corp Adiponectin production enhancer and stimulator
CN103251631A (en) * 2008-05-13 2013-08-21 根梅迪卡治疗公司 Salicylate conjugates useful for treating metabolic disorders
TWI492755B (en) 2009-12-30 2015-07-21 Metal Ind Res & Dev Ct Extract of toona sinensis from supercritical fluid extraction for treating diabetes and metabolic diseases, the preparation method and the use thereof
ES2829388T3 (en) 2010-10-30 2021-05-31 Kindex Therapeutics Llc Cis 3,4-dihydroxy-2- (3-methylbutanoyl) -5 - (- 3-methylbutyl) -4- (4-methylpentanoyl) cyclopent-2-en-1-one derivatives, enantiomerically substantially pure compositions and methods
CN102821771B (en) * 2010-12-28 2015-01-14 高雄医学大学 Extract of Toona sinensis from supercritical fluid extraction for treating diabetes and metabolic diseases, the preparation method and the use thereof
JPWO2020031952A1 (en) 2018-08-10 2021-08-26 サントリーホールディングス株式会社 Composition for suppressing increase in blood glucose level and method for suppressing increase in blood glucose level
EP4079302A4 (en) * 2019-12-20 2023-12-20 Daicel Corporation Composition for suppressing obesity

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003996A1 (en) * 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
US6451355B1 (en) * 2000-07-17 2002-09-17 Howard M. Reisner Composition to treat diabetes
US6511683B1 (en) * 1999-09-30 2003-01-28 Factors R & D Technologies Ltd. Enchinacea supplement and method of manufacture
JP2005047822A (en) * 2003-07-30 2005-02-24 Japan Research & Development Association For New Functional Foods Hyperglycemia inhibitor
US20050074447A1 (en) * 2003-10-01 2005-04-07 Papas Andreas M. Treatment for diabetic microvascular and macrovascular complications
CN1608644A (en) * 2003-10-21 2005-04-27 陈钟 Medicine capsule for treating diabetes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4497566B2 (en) * 1998-09-02 2010-07-07 株式会社 日本薬用食品研究所 Aldose reductase inhibitors and novel saponins and novel sapogenols
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US7279185B2 (en) * 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
WO2003057232A1 (en) * 2002-01-10 2003-07-17 Biosynergen, Inc. A pharmaceutical composition and functional foods for prevention and treatment of diabetes millitus
KR100993113B1 (en) * 2002-02-14 2010-11-08 기린 홀딩스 가부시키가이샤 Compositions and foods for improving lipid metabolism
US7531521B2 (en) * 2003-02-26 2009-05-12 Unigen Pharmaceuticals, Inc. Formulation for use in the prevention and treatment of carbohydrate induced diseases and conditions
EP1558271A4 (en) * 2002-10-21 2006-01-11 Metaproteomics Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
WO2004045632A1 (en) * 2002-11-12 2004-06-03 Kaneka Corporation Peroxisome proliferator-activated recetor ligand
EP1646374A1 (en) * 2003-06-16 2006-04-19 Ranbaxy Laboratories, Ltd. Extended-release tablets of metformin
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
KR100772980B1 (en) * 2004-04-01 2007-11-02 한미약품 주식회사 Controlled release formulation for oral administration of metformin
US20080248131A1 (en) * 2005-08-09 2008-10-09 Metaproteomics, Llc Protein Kinase Modulation by Hops and Acacia Products

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511683B1 (en) * 1999-09-30 2003-01-28 Factors R & D Technologies Ltd. Enchinacea supplement and method of manufacture
WO2002003996A1 (en) * 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
US6451355B1 (en) * 2000-07-17 2002-09-17 Howard M. Reisner Composition to treat diabetes
JP2005047822A (en) * 2003-07-30 2005-02-24 Japan Research & Development Association For New Functional Foods Hyperglycemia inhibitor
US20050074447A1 (en) * 2003-10-01 2005-04-07 Papas Andreas M. Treatment for diabetic microvascular and macrovascular complications
CN1608644A (en) * 2003-10-21 2005-04-27 陈钟 Medicine capsule for treating diabetes

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AGGARWAL BHARAT B ET AL: "Suppression of the nuclear factor-kappa B activation pathway by spice-derived phytochemicals - Reasoning for seasoning", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, WILEY-BLACKWELL PUBLISHING, INC, US, vol. 1030, 1 December 2004 (2004-12-01), pages 434 - 441, XP009097664, ISSN: 0077-8923, DOI: 10.1196/ANNALS.1329.054 *
ARORA DEEPA ET AL: "Immunomodulating effects of rasayana drugs in diabetics - a clinical study.", ANCIENT SCIENCE OF LIFE OCT 2002, vol. 22, no. 2, October 2002 (2002-10-01), pages 42 - 48, XP018015455, ISSN: 0257-7941 *
DATABASE WPI Week 200519, Derwent World Patents Index; AN 2005-176026, XP002699141 *
DATABASE WPI Week 200560, Derwent World Patents Index; AN 2005-583447, XP002699140 *
HOU C C ET AL: "Bacopaside III, bacopasaponin G, and bacopasides A, B, and C from Bacopa monniera", MEDICINAL & AROMATIC PLANTS ABSTRACTS, SCIENTIFIC PUBLISHERS, SCIENTIFIC PUBLISHERS, NEW DELHI - INDIA, vol. 25, no. 4, 1 August 2003 (2003-08-01), XP018007587, ISSN: 0250-4367 *
OOMAH B DAVE ET AL: "Characteristics of raspberry (Rubus idaeus L.) seed oil", FOOD CHEMISTRY, vol. 69, no. 2, March 2000 (2000-03-01), pages 187 - 193, XP002699143, ISSN: 0308-8146 *
RANA T S ET AL: "Studies on indigenous herbal remedies for diabetes mellitus in India", BIOSIS,, 15 September 1990 (1990-09-15), XP002572903 *
SUBRAMONIAM A ET AL: "EFFECTS OF ARTEMISIA PALLENS WALL. ON BLOOD GLUCOSE LEVELS IN NORMAL AND ALLOXAN-INDUCED DIABETIC RATS", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE, vol. 50, no. 1, 1 January 1996 (1996-01-01), pages 13 - 17, XP002038211, ISSN: 0378-8741, DOI: 10.1016/0378-8741(95)01329-6 *
WANG X-S ET AL: "Study on hypoglycemic polysaccharide from Centalla asiatica", CHINESE PHARMACEUTICAL JOURNAL NOVEMBER 2005 CHINESE MEDICAL ASSOCIATION CN, vol. 40, no. 22, November 2005 (2005-11-01), pages 1697 - 1700, XP009170472 *

Also Published As

Publication number Publication date
WO2007070355A3 (en) 2008-07-03
AU2006326658A1 (en) 2007-06-21
CA2632607A1 (en) 2007-06-21
EP2737897A3 (en) 2014-10-01
JP2009518429A (en) 2009-05-07
EP2737897A2 (en) 2014-06-04
WO2007070355A2 (en) 2007-06-21
EP1968559A2 (en) 2008-09-17

Similar Documents

Publication Publication Date Title
IL225198A (en) Aminotetrahydropyran compounds, pharmaceutical compositions comprising the same and the use thereof for the treatment of diabetes
IL219915A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
EP2007385A4 (en) Cardiovascular composition and use the same for the treatment of alzheimers disease
EP1991218A4 (en) Use of cyclolignans for the treatment of type 2 diabetes and as contraceptives
PL2118074T3 (en) Compounds for the prevention and treatment of cardiovascular diseases
IL184312A0 (en) Herbal compositions for the treatment of diabetes and/or conditions associated therewith
IL185277A0 (en) Pharmaceutical compositions containing roflumilast for the treatment of diabetes
WO2007100535A3 (en) Oxyntomodulin derivatives
IL173060A0 (en) Medical product expiration alerting
AP2009004960A0 (en) Co-crystals and pharmaceutical compositions comprising the same
PL2018184T3 (en) Anti-VEGF-B antibody for the treatment or prophylaxis of diabetes type II or metabolic syndrome
EP2137175A4 (en) Novel phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome
EP1982724A4 (en) Therapeutic agent for metabolic syndrome and food containing the therapeutic agent
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
EP2199295A4 (en) Compounds with 7-member cycle and the pharmaceutical use thereof for preventing and treating diabetes and metabolism syndrome
EP1968559A4 (en) Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
IL208463A (en) 2-heterocyclyl-fused pyrrole compounds, pharmaceutical compositions comprising them and their use in the prophylaxis or treatment of diabetes or obesity
EP2056857A4 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
EP2010164A4 (en) S-nitrosothiols containing compositions and the use of such compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
EP2231148A4 (en) Pharmaceutical composition for the treatment and prevention of cardiac disease
EP2170932A4 (en) Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
IL211267A (en) Oxadiazole derivatives and medicaments and use thereof for the treatment of diabetes
EP1997487A4 (en) Product for use in the prevention and treatment of cardiovascular diseases, cancer and chronic inflammatory diseases
EP2005964A4 (en) The medicament for treating hyperphospheremia and preparation thereof
ZA200705349B (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080703

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1122221

Country of ref document: HK

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/01 20060101AFI20130627BHEP

Ipc: A61K 36/48 20060101ALI20130627BHEP

Ipc: A61K 36/282 20060101ALI20130627BHEP

Ipc: A61K 36/68 20060101ALI20130627BHEP

Ipc: A61K 36/185 20060101ALI20130627BHEP

Ipc: A61K 36/73 20060101ALI20130627BHEP

Ipc: A61K 36/235 20060101ALI20130627BHEP

Ipc: A61K 36/80 20060101ALI20130627BHEP

Ipc: A61K 36/31 20060101ALI20130627BHEP

Ipc: A61K 36/23 20060101ALI20130627BHEP

Ipc: A61P 5/48 20060101ALI20130627BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20130705

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140204

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1122221

Country of ref document: HK